Navigation Links
Kelyniam Global Inc. Reports 2011 3rd & 4th Quarter Financial Results

CANTON, Conn., Feb. 16, 2012 /PRNewswire/ -- Kelyniam (Pinksheets: KLYG), is pleased to announce the 3rd and 4th quarter 2011 numbers consisting of revenues only derived from the medical device business.

While Kelyniam only received the 510k approval for Custom Skull Implants (CSI) in April of 2011, the company was thrilled to be able to receive and fulfill several orders during the 3rd quarter, even before our commercial launch in September.  Revenues for the 3rd quarter of 2011 were $63,821.  This clearly demonstrates demand for our product.

4th quarter revenues were $46,800.  Fewer surgeries were scheduled around the holidays in December and due to the real-time and custom nature of our products some orders were pushed into the first quarter of 2012.  This resulted in 4th quarter revenues slightly lower than Q3 revenues.   "2011 closes a year of major milestones for Kelyniam.  We look forward to building on the momentum in 2012," said President and CEO Tennyson Anthony.

The unaudited revenues for the 3rd and 4th quarter of 2011 are as follows:Kelyniam Global, IncorporatedCondensed Statement of Income (loss)Dec 31, 2011

Sept 30, 2011OPERATING REVENUERevenues


63,821Cost of revenue


(55,849)Gross profit(53,234)

7,972OPERATING EXPENSEGeneral, administrative and selling expenses


29,799Professional fees8,412Total operating expense




(30,240)OTHER INCOME (EXPENSE)Interest expense (net)

(1,259)Loss on sale of securities(1,680)Total other income (expense)


(1,680)NET LOSS(148,550)

(31,920)Other comprehensive loss:

--  Unrealized loss on investment securities

--Total comprehensive income (loss)


(31,920)Shares issued and outstanding


15,822,500Basic(Loss) available to common shareholders per share


(0.00)About Kelyniam Global, IncorporatedKelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at for more information.

Forward-Looking StatementsExcept for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believes," "estimate," "expect," "should," "intend," "projects," "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

For Question regarding this Press Release, please contact:

Kelyniam Global Inc.
Michael Hamblett, 800-280-8192 x3
Director of Investor Relations


SOURCE Kelyniam Global Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kelyniam Makes History With Revolutionary 24-Hour Turnaround Capabilities
2. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
3. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
4. Directors Forum: PEPFAR and the Global AIDS Response
5. Alfacell Corporation to Present at UBS Global Life Sciences Conference
6. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
7. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
8. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
9. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
10. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
11. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO) ... of Clinical Services, Education and Human Resources will be presenting ... Oncology Drugs: Health Plan Strategies for a Dynamic Market" on ... Fenrick , a consultant with the Cambridge Advisory Group, where ... The webinar will discuss the rapid growth ...
(Date:11/24/2015)... 2015 iRhythm Technologies, Inc. , a leading digital ... that it will participate in the 27th Annual Piper Jaffray Healthcare ... York, NY . Kevin King , Chief Executive ... 2015 at 8:50am ET. --> ... --> . --> iRhythm is a ...
(Date:11/24/2015)... , November 24, 2015 ... CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists ... going to grow at the fastest rates? This ... assessing data, trends, opportunities and prospects there. ,  ,Our ... the most lucrative areas in the industry and the ...
Breaking Medicine Technology:
(Date:11/24/2015)... Salt Lake City, UT (PRWEB) , ... November 24, 2015 , ... ... according to Forbes Magazine. For a business, it is critical that the first impression ... of a business, they are not likely to buy anything or want to return. ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Reactor System. Brillouin is the developer of renewable energy technologies capable of producing ... reactions (“LENR”), announced today that its WET™ and HHT™ Boiler System reactor core ...
(Date:11/24/2015)... Indianapolis, IN (PRWEB) , ... November 24, 2015 ... ... employee benefits advisory organization, is pleased to welcome Winter-Dent & Company as its ... strive from day one to become a client's most trusted advisor regardless of ...
(Date:11/24/2015)... ... November 24, 2015 , ... The American ... support their local poison centers through donations on Tuesday, Dec. 1, 2015. Since ... “a day that inspires people to collaborate in improving their local communities and ...
(Date:11/24/2015)... MI (PRWEB) , ... November 24, 2015 , ... Serenity ... released a series of recent video interviews with some of the staff members at ... at the residential treatment facility, as well as some of the things that make ...
Breaking Medicine News(10 mins):